While hepatocyte health and tumor burden were unaffected by PI3K or Mek1/2 inhibition, we found that PI3K but not Mek1/2 could potentiate the anti-proliferative effects of atorvastatin (Fig. 4). This evidence concerns the gene MAP2K1 and neoplasm.